PCRX Pacira BioSciences, Inc. Stock Quote

PCRX [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	37.66	EPS (ttm)	1.36	Insider Own	1.20%	Shs Outstand	44.48M	Perf Week	-8.26%
Market Cap	2.30B	Forward P/E	13.16	EPS next Y	3.88	Insider Trans	-8.25%	Shs Float	44.13M	Perf Month	-1.88%
Income	61.60M	PEG	1.04	EPS next Q	1.31	Inst Own	-	Short Float	14.83%	Perf Quarter	-13.42%
Sales	513.30M	P/S	4.48	EPS this Y	35.30%	Inst Trans	-0.13%	Short Ratio	14.17	Perf Half Y	-18.37%
Book/sh	16.16	P/B	3.16	EPS next Y	38.71%	ROA	4.70%	Target Price	79.92	Perf Year	-19.89%
Cash/sh	15.42	P/C	3.31	EPS next 5Y	36.10%	ROE	9.20%	52W Range	45.05 - 80.00	Perf YTD	-14.59%
Dividend	-	P/FCF	23.43	EPS past 5Y	136.60%	ROI	15.10%	52W High	-36.11%	Beta	0.97
Dividend %	-	Quick Ratio	3.30	Sales past 5Y	11.50%	Gross Margin	73.40%	52W Low	13.45%	ATR	1.83
Employees	624	Current Ratio	3.60	Sales Q/Q	8.70%	Oper. Margin	20.40%	RSI (14)	33.11	Volatility	3.76% 3.62%
Optionable	Yes	Debt/Eq	0.67	EPS Q/Q	-86.80%	Profit Margin	12.00%	Rel Volume	1.34	Prev Close	51.63
Shortable	Yes	LT Debt/Eq	0.45	Earnings	Nov 03 BMO	Payout	0.00%	Avg Volume	461.84K	Price	51.11
Recom	2.00	SMA20	-8.42%	SMA50	-6.13%	SMA200	-16.26%	Volume	613,799	Change	-1.01%

Jul-26-21

Upgrade

JP Morgan

Neutral → Overweight

$75

Apr-21-21

Resumed

JP Morgan

Neutral

$70

Apr-09-21

Initiated

Berenberg

Buy

$93

Apr-07-21

Resumed

RBC Capital Mkts

Outperform

$86

Feb-11-21

Downgrade

Northland Capital

Outperform → Market Perform

$72 → $75

Jan-21-21

Downgrade

SVB Leerink

Outperform → Mkt Perform

$75

Sep-21-20

Upgrade

Northland Capital

Market Perform → Outperform

$58 → $67

Jul-06-20

Reiterated

Needham

Buy

$52 → $64

May-27-20

Initiated

Guggenheim

Neutral

Apr-07-20

Initiated

Northland Capital

Outperform

$50

Mar-20-20

Upgrade

SVB Leerink

Mkt Perform → Outperform

$44

Feb-24-20

Reiterated

H.C. Wainwright

Buy

$60 → $63

Jan-24-20

Initiated

SunTrust

Buy

Jan-23-20

Initiated

SunTrust

Buy

Nov-06-19

Initiated

BTIG Research

Buy

$56

Jun-11-19

Initiated

Barclays

Overweight

$52

May-06-19

Upgrade

Mizuho

Underperform → Neutral

$29 → $38

May-02-19

Upgrade

Stifel

Sell → Hold

$45

Feb-01-19

Downgrade

Mizuho

Neutral → Underperform

Aug-06-18

Downgrade

BofA/Merrill

Buy → Neutral

Nov-23-21 08:00AM	Pacira BioSciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference GlobeNewswire
Nov-19-21 08:40AM	Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management GlobeNewswire
Nov-18-21 10:00AM	Those who invested in Pacira BioSciences (NASDAQ:PCRX) five years ago are up 75% Simply Wall St.
Nov-10-21 08:00AM	Pacira BioSciences to Present at the Jefferies London Healthcare Conference GlobeNewswire
Nov-09-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2021 GlobeNewswire
Nov-08-21 04:30PM	Pacira Files Lawsuit Against eVenus for Patent Infringement GlobeNewswire
Nov-03-21 01:30PM	Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark Zacks +5.15%
01:01PM	Pacira BioSciences, inc (PCRX) Q3 2021 Earnings Call Transcript Motley Fool
09:15AM	Pacira (PCRX) Beats Q3 Earnings Estimates Zacks
08:00AM	Pacira BioSciences Reports Third Quarter 2021 Financial Results GlobeNewswire
Nov-02-21 06:35PM	FLEXION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN PR Newswire
07:30AM	Pacira Receives Notice of Allowance for New Patent Covering EXPAREL Composition GlobeNewswire
Oct-27-21 07:30AM	Pacira to Report Third Quarter 2021 Financial Results on Wednesday November 3, 2021 GlobeNewswire
Oct-26-21 09:34AM	Hedge Funds Are Coming Back To Pacira Biosciences Inc (PCRX) Insider Monkey
Oct-21-21 05:25PM	Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Meredith Corporation, Aspen Technology, Flexion, and Columbia Banking System on behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
Oct-13-21 07:17PM	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Flexion Therapeutics, Inc. (Nasdaq - FLXN) ACCESSWIRE
12:40PM	FLEXION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FLXN and Encourages Investors to Contact the Firm GlobeNewswire
Oct-12-21 12:00PM	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Flexion Therapeutics, Inc. Merger GlobeNewswire
Oct-11-21 11:41PM	SHAREHOLDER ALERT: WeissLaw LLP Investigates Flexion Therapeutics, Inc. PR Newswire +5.82%
04:26PM	ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc. PR Newswire
08:07AM	(FLXN): Johnson Fistel Investigates Proposed Sale of Flexion; Are Shareholders Getting a Fair Deal? GlobeNewswire
07:52AM	Pacira BioSciences Nears $630 Million Deal for Flexion Bloomberg
07:00AM	Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management GlobeNewswire
Oct-08-21 08:00AM	Pacira BioSciences to Host Investor Day on October 15th, 2021 in Tampa, FL GlobeNewswire
Oct-05-21 08:57AM	Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down Zacks
Oct-04-21 03:56PM	Why Pacira Biosciences Stock Sank Today Motley Fool -13.22%
01:26PM	These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely Simply Wall St.
07:30AM	Pacira BioSciences Notified of Abbreviated New Drug Application Filing for EXPAREL® GlobeNewswire
Sep-30-21 07:30AM	Pacira Announces Commercial Production Underway with Enhanced EXPAREL Manufacturing Process at Swindon Facility GlobeNewswire
Sep-21-21 07:30AM	Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries GlobeNewswire
Sep-15-21 07:30AM	Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021 GlobeNewswire
Sep-08-21 08:00AM	Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Sep-02-21 11:31AM	Pacira (PCRX) Down 1.6% Since Last Earnings Report: Can It Rebound? Zacks
Aug-10-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021 GlobeNewswire -7.23%
Aug-05-21 06:50AM	Will Weakness in Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Prove Temporary Given Strong Fundamentals? Simply Wall St.
Aug-04-21 10:38AM	Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y Zacks
Aug-03-21 06:30PM	Pacira BioSciences, inc (PCRX) Q2 2021 Earnings Call Transcript Motley Fool
09:15AM	Pacira (PCRX) Q2 Earnings Surpass Estimates Zacks
08:00AM	Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021 GlobeNewswire
Aug-02-21 10:26AM	10 Best Stocks to Buy According to John Paulson Insider Monkey
08:00AM	Pacira Announces FDA Approval of Enhanced EXPAREL Manufacturing Process GlobeNewswire
Jul-29-21 07:30AM	New Analysis Shows iovera° Plays a Critical Role in Achieving Significant Reductions in Opioid Use, Pain Scores, and Hospital Stay Following Total Knee Arthroplasty GlobeNewswire
Jul-27-21 03:03PM	Pacira (PCRX) Earnings Expected to Grow: Should You Buy? Zacks
Jul-21-21 10:14AM	Hedge Fund Sentiment Is Stagnant On Pacira Biosciences Inc (PCRX) Insider Monkey
Jul-20-21 07:30AM	Pacira to Report Second Quarter 2021 Financial Results on Tuesday August 3, 2021 GlobeNewswire
Jul-13-21 08:00AM	Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021 GlobeNewswire
Jun-22-21 08:00AM	Pacira Announces EXPAREL Distribution Agreement with Eurofarma in Latin America GlobeNewswire
Jun-08-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $42.2 Million for May 2021 GlobeNewswire
Jun-03-21 11:31AM	How Has PCRX Performed 30 Days Post Earnings Zacks
May-26-21 09:23AM	Pacira BioSciences' Exparel Misses Primary Endpoint In Post-Op Pain Study After Lower Extremity Surgeries Benzinga
08:00AM	Pacira BioSciences Announces Top-line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block GlobeNewswire
May-25-21 08:00AM	Pacira BioSciences to Present at the 2021 Jefferies Virtual Healthcare Conference GlobeNewswire
May-18-21 08:00AM	Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL GlobeNewswire
May-12-21 08:00AM	Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-11-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021 GlobeNewswire
May-05-21 08:11AM	Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat Zacks
May-04-21 02:30PM	Pacira BioSciences, Inc. (PCRX) Q1 2021 Earnings Call Transcript Motley Fool
09:15AM	Pacira (PCRX) Q1 Earnings Lag Estimates Zacks
08:00AM	Pacira BioSciences Reports First Quarter 2021 Financial Results and Business Update GlobeNewswire
06:45AM	Pacira Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Apr-21-21 07:30AM	Pacira to Report First Quarter 2021 Financial Results on Tuesday May 4, 2021 GlobeNewswire
Apr-20-21 07:30AM	Spine BioPharma Announces Investment by Pacira Biosciences PR Newswire
07:30AM	Pacira BioSciences Announces Investment in Spine BioPharma GlobeNewswire
Apr-14-21 04:00PM	Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology GlobeNewswire
Apr-07-21 08:00AM	Pacira Reports Preliminary Net Product Sales of $118.7 Million for the First Quarter of 2021 GlobeNewswire
Mar-30-21 05:46AM	Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly Simply Wall St.
Mar-27-21 11:31AM	Pacira (PCRX) Down 3.6% Since Last Earnings Report: Can It Rebound? Zacks
Mar-23-21 09:36AM	Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients Zacks
Mar-22-21 06:42PM	Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® (bupivacaine liposome injectable suspension) in Pediatric Patients GlobeNewswire
Mar-17-21 01:10PM	Halozyme Stock Joins The 80-Plus RS Rating Club Investor's Business Daily
Mar-15-21 01:05PM	Stocks Showing Leadership: Covid Recovery Play Ligand Earns Key Rating Jump Investor's Business Daily
Mar-09-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $36.2 Million for February 2021 GlobeNewswire
Mar-03-21 07:30AM	Pacira BioSciences to Present at the 2021 Barclays Global Healthcare Conference GlobeNewswire
Feb-26-21 08:58AM	Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss Zacks
Feb-25-21 04:01PM	Pacira BioSciences, Inc. (PCRX) Q4 2020 Earnings Call Transcript Motley Fool -5.54%
08:00AM	Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results GlobeNewswire
06:30AM	Pacira Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Feb-23-21 02:49PM	Pacira Pharmaceuticals Getting Closer To Key Technical Measure Investor's Business Daily
Feb-18-21 07:30AM	Pacira to Report 2020 Financial Results on Thursday February 25, 2021 GlobeNewswire
Feb-14-21 01:32PM	15 Best Small-Cap Healthcare Stocks to Buy Insider Monkey
Feb-10-21 07:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $36.0 Million for January 2021 GlobeNewswire
Jan-29-21 03:32AM	Here's Why I Think Pacira BioSciences (NASDAQ:PCRX) Is An Interesting Stock Simply Wall St.
Jan-26-21 03:39PM	Composite Rating For Pacira Pharmaceuticals Rises To 97 Investor's Business Daily
08:00AM	Pacira BioSciences Announces Equity Investment in GeneQuine Biotherapeutics GlobeNewswire
Jan-15-21 11:40AM	AMRX or PCRX: Which Is the Better Value Stock Right Now? Zacks
Jan-12-21 12:48PM	Exact Sciences Scores Relative Strength Rating Upgrade; Hits Key Threshold Investor's Business Daily
Jan-08-21 04:18PM	Stocks Rebound Into The Close; Tesla Contributes To Nasdaq 100's 1.3% Jump Investor's Business Daily
Jan-07-21 04:10PM	Nasdaq Soars As Indexes Hit Record Highs; Medical, Energy, Auto Stocks Among Breakouts Investor's Business Daily +7.50%
07:30AM	Pacira Reports Record Revenue for 2020 of $429.6 Million GlobeNewswire
Jan-06-21 07:30AM	Pacira BioSciences to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-15-20 02:39AM	Pacira BioSciences (NASDAQ:PCRX) Shareholders Booked A 38% Gain In The Last Three Years Simply Wall St.
Dec-09-20 04:40PM	Dow Jones Falls, Nasdaq Leads Market Lower On Stimulus Talks Investor's Business Daily -7.41%
07:30AM	Pacira BioSciences Reports Preliminary Net Product Sales of $38.9 Million for November 2020 GlobeNewswire
Nov-24-20 07:30AM	Pacira BioSciences to Present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire
Nov-19-20 10:08AM	Pacira (PCRX) Gets European Commission Approval for Exparel Zacks
Nov-18-20 07:30AM	Pacira Receives European Commission Approval for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain GlobeNewswire
Nov-16-20 01:48PM	Dow Jones Rises 330 Points To Record High On Positive Vaccine Data Investor's Business Daily
Nov-13-20 10:40AM	Pacira Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
Nov-11-20 01:27PM	IBD 50 Stocks To Watch: This Pharma Stock On 115% Run Eyes Buy Point Investor's Business Daily
08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $41.7 Million for October 2020 GlobeNewswire

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LARANJEIRA CHARLES ANTHONY	Chief Technical Officer	Nov 22	Option Exercise	44.10	7,500	330,750	33,602	Nov 24 04:25 PM
STACK DAVID M	CEO and Chairman	Nov 16	Option Exercise	10.81	15,000	162,150	94,085	Nov 18 04:22 PM
WINSTON ROY	Chief Medical Officer	Nov 04	Option Exercise	48.15	10,000	481,500	46,456	Nov 08 04:22 PM
Riker Lauren Bullaro	Vice President, Finance	Jul 29	Option Exercise	10.81	90	973	13,242	Jul 30 04:21 PM
Riker Lauren Bullaro	Vice President, Finance	Jul 29	Sale	60.81	90	5,473	13,152	Jul 30 04:21 PM
Riker Lauren Bullaro	Vice President, Finance	Jul 28	Option Exercise	10.81	2,410	26,052	15,562	Jul 30 04:21 PM
Riker Lauren Bullaro	Vice President, Finance	Jul 28	Sale	60.85	2,410	146,648	13,152	Jul 30 04:21 PM
REINHARDT MAX	President, Rest of World	Jul 02	Sale	59.76	421	25,159	17,500	Jul 06 06:14 PM
Riker Lauren Bullaro	Vice President, Finance	Jun 11	Sale	59.85	2,003	119,880	12,731	Jun 11 08:39 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 10	Sale	59.60	5,689	339,063	22,268	Jun 11 08:38 PM
Manning Donald C.	Chief Medical Officer	Jun 08	Sale	61.14	2,600	158,964	23,520	Jun 10 06:07 PM
REINHARDT MAX	President, Rest of World	Jun 07	Sale	60.50	2,278	137,819	10,500	Jun 08 04:16 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 04	Sale	61.04	3,930	239,875	20,957	Jun 08 04:20 PM
WINSTON ROY	Chief Clinical Officer	Jun 04	Sale	61.04	2,276	138,920	24,035	Jun 08 04:20 PM
STACK DAVID M	CEO and Chairman	Jun 04	Sale	61.04	14,905	909,756	61,156	Jun 08 04:18 PM
Reinhart Charles A. III	Chief Financial Officer	Jun 04	Sale	61.04	2,648	161,626	24,799	Jun 08 04:17 PM
Riker Lauren Bullaro	Vice President, Finance	Jun 04	Sale	61.04	1,047	63,906	12,134	Jun 08 04:17 PM
REINHARDT MAX	President, Rest of World	Jun 04	Sale	61.04	1,222	74,587	12,778	Jun 08 04:16 PM
McLoughlin Dennis	Chief Customer Officer	Jun 04	Sale	61.04	1,895	115,665	27,541	Jun 08 04:15 PM
LARANJEIRA CHARLES ANTHONY	Chief Technical Officer	Jun 04	Sale	61.04	2,117	129,215	18,681	Jun 08 04:14 PM
HASTINGS PAUL J	Director	Jun 04	Sale	62.19	630	39,180	5,486	Jun 08 04:13 PM
Manning Donald C.	Chief Medical Officer	Jun 02	Sale	62.12	2,380	147,853	26,120	Jun 04 05:27 PM
STACK DAVID M	CEO and Chairman	May 12	Option Exercise	10.81	21,250	229,712	97,311	May 13 06:01 PM
STACK DAVID M	CEO and Chairman	May 12	Sale	61.95	21,250	1,316,471	76,061	May 13 06:01 PM
STACK DAVID M	CEO and Chairman	May 11	Option Exercise	10.81	21,250	229,712	97,311	May 13 06:01 PM
STACK DAVID M	CEO and Chairman	May 11	Sale	60.93	21,250	1,294,827	76,061	May 13 06:01 PM
Williams Kristen Marie	Chief Administrative Officer	Apr 13	Option Exercise	40.28	21,823	878,943	46,710	Apr 15 08:35 PM
Williams Kristen Marie	Chief Administrative Officer	Apr 13	Sale	66.95	21,823	1,461,068	24,887	Apr 15 08:35 PM
WINSTON ROY	Chief Clinical Officer	Mar 31	Option Exercise	34.38	13,750	472,656	48,535	Apr 02 06:33 PM
WINSTON ROY	Chief Clinical Officer	Mar 31	Sale	70.61	22,224	1,569,195	26,311	Apr 02 06:33 PM
Riker Lauren Bullaro	Vice President, Finance	Mar 17	Option Exercise	10.81	2,000	21,620	15,181	Mar 17 08:03 PM
Riker Lauren Bullaro	Vice President, Finance	Mar 17	Sale	70.01	2,000	140,020	13,181	Mar 17 08:03 PM
Riker Lauren Bullaro	Vice President, Finance	Mar 15	Option Exercise	10.81	1,520	16,431	14,701	Mar 17 08:03 PM
Riker Lauren Bullaro	Vice President, Finance	Mar 15	Sale	73.28	1,520	111,386	13,181	Mar 17 08:03 PM
Froimson Mark	Director	Mar 15	Sale	72.26	734	53,039	5,242	Mar 17 08:01 PM
Wicki Andreas	Director	Mar 15	Sale	73.68	10,601	781,082	451,324	Mar 16 09:12 PM
Wicki Andreas	Director	Mar 12	Sale	73.10	58,754	4,294,917	461,925	Mar 16 09:12 PM
Wicki Andreas	Director	Mar 11	Sale	72.70	60,574	4,403,730	520,679	Mar 11 09:37 PM
Wicki Andreas	Director	Mar 10	Sale	71.78	76,480	5,489,734	581,253	Mar 11 09:37 PM
Wicki Andreas	Director	Mar 09	Sale	70.90	35,137	2,491,213	657,733	Mar 11 09:37 PM
HASTINGS PAUL J	Director	Mar 05	Option Exercise	13.98	3,000	41,940	9,116	Mar 09 04:12 PM
HASTINGS PAUL J	Director	Mar 05	Sale	65.88	3,000	197,640	6,116	Mar 09 04:12 PM
LONGENECKER JOHN P PHD	Director	Mar 01	Option Exercise	13.98	5,000	69,900	22,757	Mar 03 04:25 PM
LONGENECKER JOHN P PHD	Director	Mar 01	Sale	72.26	5,000	361,300	17,757	Mar 03 04:25 PM
STACK DAVID M	CEO and Chairman	Feb 03	Option Exercise	10.81	21,250	229,712	97,311	Feb 04 07:58 PM
STACK DAVID M	CEO and Chairman	Feb 03	Sale	71.21	21,250	1,513,259	76,061	Feb 04 07:58 PM
STACK DAVID M	CEO and Chairman	Feb 02	Option Exercise	10.81	21,250	229,712	97,311	Feb 04 07:58 PM
STACK DAVID M	CEO and Chairman	Feb 02	Sale	69.41	21,250	1,474,874	76,061	Feb 04 07:58 PM
REINHARDT MAX	President	Jan 06	Sale	60.81	110	6,689	14,000	Jan 08 04:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience